<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR941019-2-00079</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=1 --> The role of the successful corporate partner will include:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 1. Obtain background license in appropriate fields of use to the relevant Government patent rights.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2. Purify to homogeneity 30&hyph;50 milligrams of CR&hyph;1 from  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Pichia pastoris <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  conditioned medium.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3. Provide the purified recombinant CR&hyph;1 protein.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 4. Utilize the purified recombinant CR&hyph;1 protein to generate mouse anti-CR&hyph;1 monoclonal antibodies.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 5. Screen anti-CR&hyph;1 monoclonal antibodies for specificity, reactivity, and sensitivity toward recombinant CR&hyph;1 protein.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 6. Ascertain whether monoclonal anti-CR&hyph;1 antibodies can detect native CR&hyph;1 protein in CR&hyph;1 positive human colorectal or embryonal carcinoma cells by radioimmunoprecipitation analysis and by ELISA.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 7. Determine whether anti-CR&hyph;1 antibodies can be used for ICC on formalin-fixed, paraffin embedded tissues known for CR&hyph;1 expression.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 8. Provide funds to support associated CRADA-related research expenses including supplies, reagents, travel, and training.  <!-- PJG 0012 frnewline --> Criteria for choosing the collaborating company will include:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 1. Ability to obtain background license to relevant patent rights.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2. Experience in producing and purifying recombinant proteins, particularly growth factors or cytokines.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3. Experience in generating and screening monoclonal antibodies.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 4. Willingness to cooperate with the NCI in the collection and evaluation of data.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 5. Willingness to cost share in laboratory studies.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 6. An agreement to be bound by the DHHS rules involving the use of human and animal subjects, and human tissue.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 7. Provisions for equitable distribution of patent rights to any inventions. Generally the rights of ownership are retained by the organization which is the employer of the inventor, with (1) an irrevocable, nonexclusive, royalty-free license to the Government (when a company employee is the sole inventor) or (2) an exclusive or nonexclusive license to the company on terms that are appropriate (when the Government employee is the sole inventor).  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: Octber 13, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Barbara M. McGarey,  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Deputy Director, Office of Technology Transfer. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;25922 Filed 10&hyph;18&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4140&hyph;01&hyph;P <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            